1.Metagenomic next-generation sequencing in diagnosis of non-tuberculous mycobacterial bone and joint infections
Guangxuan YAN ; Xueyu WANG ; Wenjuan NIE
Chinese Journal of Clinical Infectious Diseases 2025;18(1):25-29
Objective:To evaluate the diagnostic value of metagenomic next-generation sequencing(mNGS)in bone and joint infections caused by non-tuberculous mycobacteria(NTM).Methods:Clinical data of 175 patients with suspected NTM bone and joint infections admitted in Beijing Chest Hospital,Capital Medical University from January 2019 to January 2023 were retrospectively analyzed. Mycobacterium growth indicator tube(MGIT)method was used for mycobacterial culture on the bone tissue or abscess samples and mNGS test was performed on bone tissue samples in all patients. Taking clinical diagnosis as the gold standard,the sensitivity,specificity,positive predictive value,negative predictive value,positive likelihood ratio,and negative likelihood ratio of the two methods were compared.Results:Twenty-six patients(14.9%)were clinically diagnosed as NTM bone and joint infections. The mNGS showed higher sensitivity(100.0% vs. 57.7%,),specificity(99.3% vs. 86.6%),positive predictive value(96.3% vs. 42.9%),and negative predictive value(100.0% vs. 92.1%),compared to MGIT culture(all P<0.001). The positive likelihood ratio(149.00 vs. 4.31)and negative likelihood ratio(0 vs. 0.49)of mNGS were also superior to those of MGIT. Conclusion:Compared to MGIT culture,mNGS has high diagnostic value in NTM bone and joint infections and can serve as an efficient and reliable method for clinical diagnosis.
2.Metagenomic next-generation sequencing in diagnosis of non-tuberculous mycobacterial bone and joint infections
Guangxuan YAN ; Xueyu WANG ; Wenjuan NIE
Chinese Journal of Clinical Infectious Diseases 2025;18(1):25-29
Objective:To evaluate the diagnostic value of metagenomic next-generation sequencing(mNGS)in bone and joint infections caused by non-tuberculous mycobacteria(NTM).Methods:Clinical data of 175 patients with suspected NTM bone and joint infections admitted in Beijing Chest Hospital,Capital Medical University from January 2019 to January 2023 were retrospectively analyzed. Mycobacterium growth indicator tube(MGIT)method was used for mycobacterial culture on the bone tissue or abscess samples and mNGS test was performed on bone tissue samples in all patients. Taking clinical diagnosis as the gold standard,the sensitivity,specificity,positive predictive value,negative predictive value,positive likelihood ratio,and negative likelihood ratio of the two methods were compared.Results:Twenty-six patients(14.9%)were clinically diagnosed as NTM bone and joint infections. The mNGS showed higher sensitivity(100.0% vs. 57.7%,),specificity(99.3% vs. 86.6%),positive predictive value(96.3% vs. 42.9%),and negative predictive value(100.0% vs. 92.1%),compared to MGIT culture(all P<0.001). The positive likelihood ratio(149.00 vs. 4.31)and negative likelihood ratio(0 vs. 0.49)of mNGS were also superior to those of MGIT. Conclusion:Compared to MGIT culture,mNGS has high diagnostic value in NTM bone and joint infections and can serve as an efficient and reliable method for clinical diagnosis.
3.Expert consensus of anti-tumor drugs prescription review: kidney cancer
Min LIU ; Wei MIAO ; Chao ZHANG ; Jie ZHANG ; Yuanyuan DAI ; Mei DONG ; Jiang LIU ; Hongbing HUANG ; Qing ZHAI ; Yuguo LIU ; Ting XU ; Ping HUANG ; Wenzhou ZHANG ; Gang JIANG ; Junling CAO ; Lixia WANG ; Yancai SUN ; Mingyan JIANG ; Yongning LYU ; Xiaoyang LU ; Maobai LIU ; Ningsheng LIANG ; Zhu DAI ; Yanqing SONG ; Pengmei LI ; Guangxuan LIU ; Zhiying HAO ; Dunwu YAO ; Guiru LI ; Shujia KONG ; Ruixiang XIE ; Jianhua WANG ; Qing WEI ; Lechuan JIA ; Mei LI ; Jun MENG ; Fang CAO ; Hongzhe SHI ; Dan YAN ; Zaixian BAI ; Chen WANG ; Guohui LI ; Jie HE
Adverse Drug Reactions Journal 2021;23(6):285-292
Kidney cancer usually requires multidisciplinary individualized treatments. No matter what kind of treatment, drugs are essential. According to the "six-step process" (prescription legitimacy review, patient basic information evaluation review, treatment protocol review, organ function and laboratory index review, pretreatment review, and unconventional prescription review) in prescription review proposed by the anti-tumor drug prescription review expert group and referring to domestic and foreign kidney cancer guidelines and drug instructions in recent years, this consensus selects 9 targeted drugs and 4 immunotherapeutic drugs that are currently commonly used in China and elaborates the key review points in patient basic information evaluation review, treatment protocol review, and organ function and laboratory index review of kidney cancer drug treatment, in order to provide reference for clinical front-line pharmacists to review prescriptions of kidney cancer patients and promote rational drug use in clinic.
4.Expert consensus of anti-tumor drugs prescription review: kidney cancer
Min LIU ; Wei MIAO ; Chao ZHANG ; Jie ZHANG ; Yuanyuan DAI ; Mei DONG ; Jiang LIU ; Hongbing HUANG ; Qing ZHAI ; Yuguo LIU ; Ting XU ; Ping HUANG ; Wenzhou ZHANG ; Gang JIANG ; Junling CAO ; Lixia WANG ; Yancai SUN ; Mingyan JIANG ; Yongning LYU ; Xiaoyang LU ; Maobai LIU ; Ningsheng LIANG ; Zhu DAI ; Yanqing SONG ; Pengmei LI ; Guangxuan LIU ; Zhiying HAO ; Dunwu YAO ; Guiru LI ; Shujia KONG ; Ruixiang XIE ; Jianhua WANG ; Qing WEI ; Lechuan JIA ; Mei LI ; Jun MENG ; Fang CAO ; Hongzhe SHI ; Dan YAN ; Zaixian BAI ; Chen WANG ; Guohui LI ; Jie HE
Adverse Drug Reactions Journal 2021;23(6):285-292
Kidney cancer usually requires multidisciplinary individualized treatments. No matter what kind of treatment, drugs are essential. According to the "six-step process" (prescription legitimacy review, patient basic information evaluation review, treatment protocol review, organ function and laboratory index review, pretreatment review, and unconventional prescription review) in prescription review proposed by the anti-tumor drug prescription review expert group and referring to domestic and foreign kidney cancer guidelines and drug instructions in recent years, this consensus selects 9 targeted drugs and 4 immunotherapeutic drugs that are currently commonly used in China and elaborates the key review points in patient basic information evaluation review, treatment protocol review, and organ function and laboratory index review of kidney cancer drug treatment, in order to provide reference for clinical front-line pharmacists to review prescriptions of kidney cancer patients and promote rational drug use in clinic.
5.Emerging transporter-targeted nanoparticulate drug delivery systems.
Hongyan SU ; Yan WANG ; Shuo LIU ; Yue WANG ; Qian LIU ; Guangxuan LIU ; Qin CHEN
Acta Pharmaceutica Sinica B 2019;9(1):49-58
Transporter-targeted nanoparticulate drug delivery systems (nano-DDS) have emerged as promising nanoplatforms for efficient drug delivery. Recently, great progress in transporter-targeted strategies has been made, especially with the rapid developments in nanotherapeutics. In this review, we outline the recent advances in transporter-targeted nano-DDS. First, the emerging transporter-targeted nano-DDS developed to facilitate oral drug delivery are reviewed. These include improvements in the oral absorption of protein and peptide drugs, facilitating the intravenous-to-oral switch in cancer chemotherapy. Secondly, the recent advances in transporter-assisted brain-targeting nano-DDS are discussed, focusing on the specific transporter-based targeting strategies. Recent developments in transporter-mediated tumor-targeting drug delivery are also discussed. Finally, the possible transport mechanisms involved in transporter-mediated endocytosis are highlighted, with special attention to the latest findings of the interactions between membrane transporters and nano-DDS.

Result Analysis
Print
Save
E-mail